All News
How often do you ask about #fatigue, #depression & #anxiety in pts with RMDs?
Study of >1000 pts found anxiety symptoms in 1/3 pts and significant association between fatigue & anxiety and depression
Highlights importance of regular review of MH symptoms
Ab2657 #ACR24 @RheumNow https://t.co/0zMOMybrCI
Mrinalini Dey DrMiniDey ( View Tweet)
A#2652
NEWTON study 🇫🇷 Retrosp cohort
51% relapse. Median @8.7 mos, dose 9mg pred
Rf: limb art involv- HR 1.9
Pred taper speed not risk for relapse
Most relapse -> incr GCs
Toci 1/3 at dx, 50% stopped
-61% d/c due to remission, 39% SEs
-1/3 relapse after d/c
@RheumNow #ACR24 https://t.co/NP0wieDmvo
Eric Dein ericdeinmd ( View Tweet)
How do you manage DMARDs when giving the recombinant #zoster #vaccine (#RZV)?
➡️75 pts with ARDs
đź’‰2-week #MTX discontinuation after each dose of RZV
⏩Significant boost in immune response without difference in flare rates
Ab2612 #ACR24 @RheumNow https://t.co/o4iqj3e1Be
Mrinalini Dey DrMiniDey ( View Tweet)
A re-evaluation of lupus arthritis. Old dogma is RA is erosive and SLE non-erosive. With better imaging, lupus arthritis can be erosive. Vivianne Malstrom. @RheumNow #ACR24 https://t.co/JEqVPLGNfu
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Did you know?
#Lupus arthritis have clinical and US classifications.
On MRI, findings will show:
- periarticular hyperplastic tissue
- capsular swelling
- edematous tenosynovitis
@RheumNow #ACR24 @rheumarhyme @theactiverheum https://t.co/EoKh2Q3V9Z
Links:
sheila RHEUMarampa ( View Tweet)
A systematic review & meta-analysis by Dr. JBCorrea et al show that the ff immune-mediated dses are assocd w/⬆️ ocurrence risk after covid19 infection 👇
Behcets
SpA
SS
SLE
PMR
Pso
RA
Sjogrens
T1DM
Vasculitis
IBD
Ask prior covid infexn in pts history
@RheumNow #ACR24 abs2614 https://t.co/TIEglPrmvL
sheila RHEUMarampa ( View Tweet)
Sharma @Amansharmapgi et al. DADA2. Clinical manifestations of 101(!) patients. @RheumNow #ACR24 Abstr#2647 https://t.co/Tkk6Rz6rtT https://t.co/frvFPYy4xf
Links:
Richard Conway RichardPAConway ( View Tweet)
Medeiros-Ribeiro et al. Holding MTX for 2 weeks after recombinant zoster vaccine increases response with no increase in flare. @RheumNow #ACR24 Abstr#2612 https://t.co/NEop0XB5Ak https://t.co/P4S2qzbkTs
Links:
Richard Conway RichardPAConway ( View Tweet)
SmPCs recommend interrupting immunosuppression (IS) in infection
What happens if you continue the drug?
Ab2611 found no difference in infection outcomes btwn temp interruption & continuation of IS in infection
Could continuation be a safe option in some pts?
#ACR24 @RheumNow https://t.co/14SN6a4Wm8
Mrinalini Dey DrMiniDey ( View Tweet)
Evaluation of Bimekizumab in PsA
At last year’s ACR, I shared about the early clinical trial data on bimekizumab in psoriatic arthritis. Bimekizumab (BKZ), a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)‑17A and F. There have been more updates on the 2… https://t.co/lphZUiiq5T https://t.co/zuHpBaMtEv
Dr. John Cush RheumNow ( View Tweet)
Zou et al. Phase 2 RCT Vunakizumab, humanized IL17A in PsA. 12 week study. ACR responses shown in figure, looks similar to existing IL17As. @RheumNow #ACR24 Abstr#2581 https://t.co/Td5xlMYrAd https://t.co/Rl4gkmDFOR
Links:
Richard Conway RichardPAConway ( View Tweet)
#2286🔬Certolizumab Pegol (CZP) in High RF RA
đź“ŠPooled analysis;N=1180
đź’ĄPBO: High RF=more radiographic progression v low RF (Wk24 6.5 v 2.8%,Wk52 17.6 v 10.4%)
đź’ĄCZP: min. progression regardless of RF (Wk24 0 v 1.1%;Wk52 5.3 v 3.1%)
#ACR24 @RheumNow https://t.co/koel7SDsUb
Caoilfhionn Connolly CaoilfhionnMD ( View Tweet)
Triboulet et al. JAKi in RA-ILD. 42 patients. Stability of PFTs over median 21 months. HRCT stable in 62%. Progressive ILD on HRCT in 19%. @RheumNow #ACR24 Abstr#2249 https://t.co/PY9BrCfNHc https://t.co/r8fIgrjyDu
Links:
Richard Conway RichardPAConway ( View Tweet)
Tesser et al. Implanted cervical vagus nerve stimulator for b/tsDMARD-IR RA. 242 patients. ACR20 week 12 35% vs 24%. Higher rates of DAS28-CRP LDA/remission. @RheumNow #ACR24 Abstr#L10 https://t.co/OXojHEMkKQ https://t.co/XSt97u7LrR
Links:
Richard Conway RichardPAConway ( View Tweet)
@DianeLacaille Canadian biosimilar exp
Biosimilar transition v originator controls x2 yrs
Weighted model: no decr in ETN biosimilar discontinuation v originator. IFX shows slight decrease - NOT statistical signif
Safety- no difference, slight incr rheum visits
@RheumNow #ACR24 https://t.co/0GMfLAyzOo
Eric Dein ericdeinmd ( View Tweet)
Galloway et al. 117,050 individuals. VTE risk in RA consistently increased, irrespective of age, sex, BMI. Risk VTE 46% higher in RA! @RheumNow #ACR24 Abstr#1901 https://t.co/SQPcPiBeF2 https://t.co/BQkERUsGlL
Links:
Richard Conway RichardPAConway ( View Tweet)
Abstract 1842: Off the shelf CAR T therapy
No lymphodepletion needed, delivering robust, targeted CD19+ B cell elimination in multiple in vitro assays
@RheumNow #ACR24
Akhil Sood MD AkhilSoodMD ( View Tweet)
Non-pharm tx in TAK - not something we always think about but…
Impressive effect of resistance exercise!!
Not just in symptoms but also inflammatory markers
Per Dr. Springer - even a stress ball could be enough for UE vascular health in these pt
@RheumNow #ACR24 https://t.co/3O46gobbMX
Links:
Brian Jaros, MD Dr_Brian_MD ( View Tweet)
Overall very reasonable, aligning ACR recs w/other guidance groups & updated data
Remember: guidelines are meant to be broken. Some patients can likely avoid pulse, others may need more steroid on the back end, biopsies are not benign
#ACR24 @RheumNow
Mike Putman EBRheum ( View Tweet)
Recommend "Triple Therapy" = Glucocorticoids + two other agents
Practically, that means MMF + belimumumab OR CNI for most pts
For the CYC afficionados, the lower-dose EUROLUPUS protocol is preferred
#ACR24 @RheumNow https://t.co/0gRISXSw0c
Mike Putman EBRheum ( View Tweet)
